RxDoctor Payments Data

Suhash Patel, DO

Cardiovascular Disease · Bridgeport, CTNPI 1437318649

Payments from drug & device makers

$1,058in general payments, 2019–2025

Across 55 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$250
  • Novartis$231
  • Johnson & Johnson$202
  • E.r. Squibb & Sons, L.L.C.$82
  • Sanofi-aventis U.S. LLC$50
  • AstraZeneca$46
  • plus $197 from 8 others

What the payments were for

  • Food & beverage$1,058100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,058 in reported general payments places this provider in the 45th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$169,717
Medicare patients
614
Services billed
2,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis17$382,558
EliquisApixaban116$150,324
EntrestoSacubitril/Valsartan32$50,230
JardianceEmpagliflozin16$21,995
XareltoRivaroxaban12$16,130
Repatha SureclickEvolocumab11$10,425
Atorvastatin Calcium148$1,927
Metoprolol Succinate139$1,754
Clonidine16$1,716
Amlodipine Besylate127$981
Midodrine Hcl14$784
Losartan Potassium91$779
Rosuvastatin Calcium61$748
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$634
Furosemide123$613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$231$50,23032 claims
Boehringer IngelheimJardiance$250$21,99516 claims
Johnson & JohnsonXarelto$202$16,13012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →